A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)

Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We evaluated the efficacy and safety of t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Res
Autori principali: Sallman, David A., Komrokji, Rami S., Sweet, Kendra L., Mo, Qianxing, McGraw, Kathy L., Duong, Vu H., Zhang, Ling, Nardelli, Lisa Ann, Padron, Eric, List, Alan F., Lancet, Jeffrey E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787349/
https://ncbi.nlm.nih.gov/pubmed/31030089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2019.03.008
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi